RPE65 and inherited retinal dystrophy: Another FDA-approved AAV-based gene therapy medication is Luxturna, which is intended for the treatment of retinal dystrophy caused by biallelic mutations in the RPE65 gene (an enzyme of retinal cells involved in light-sensitive pigment regeneration).